Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 6Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 17Carcinoma, Ovarian Epithelial 12Breast Neoplasms 8Fallopian Tube Neoplasms 7Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Squamous Cell Carcinoma of Head and Neck 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Colonic Neoplasms 2

Interventions

pembrolizumab 42Nivolumab 13Carboplatin 11Cyclophosphamide 10olaparib 7Paclitaxel 7Ipilimumab 7fludarabine 6Gemcitabine 6durvalumab 5lenvatinib 4cemiplimab 4atezolizumab 4Specimen Handling 4Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fulvestrant 4Fluorouracil 4Cisplatin 4Bevacizumab 4veliparib 3spartalizumab 3sacituzumab govitecan 3liposomal doxorubicin 3avelumab 3aldesleukin 3Taxes 3Interleukin-2 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × sargramostim × Gynecologic × Clear all
NCT05269381 2026-03-12

PNeoVCA

Mayo Clinic

Phase 1/2 Recruiting
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡